Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ixazomib and rituximab work in treating patients with
mantle cell lymphoma that has come back (relapsed) or does not respond (refractory) to BTK
inhibitor treatment. Ixazomib may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth. Immunotherapy with rituximab may induce changes in body's
immune system and may interfere with the ability of tumor cells to grow and spread. Giving
ixazomib and rituximab may work better in treating patients with mantle cell lymphoma
compared to rituximab alone.